Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Small-Molecule GLP-1 Receptor Agonist in Obesity
The first annual report under an IND is often the first time a sponsor has to reconcile clinical, safety, nonclinical, and manufacturing information from several functions against one data cutoff. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND for an oral, nonpeptide GLP-1 receptor agonist in adults with obesity. It accounts for a completed Phase 1 study (48 entered) and an ongoing Phase 2 study (92 of 150 planned entered), reports one IND safety report, an excipient supplier change, and a revision of the Investigator's Brochure, maps each element of 21 C.F.R. 312.33 to Module 1.13 of the eCTD, and sets out Form FDA 1571 entries, a draft cover letter, and a timeline to a January 30, 2027 deadline. It closes with the operational challenges that most often cause inconsistent or incomplete reports and how to prevent them.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle
Authors
- Peivand Pirouzi
- Riddhi Rohan Moradiya
- Aditi Shivakumar Hipparagi
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24420527
- Primary Topic
- Healthcare Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00